Combining a diabetes drug with a cancer drug not only kills aggressive bladder cancer cells in mice, but also turns remaining malignant cells into a more benign state.
Immunotherapy has been disappointing as treatment for prostate cancer, but a new Columbia trial suggests it has potential for treating metastatic disease.
After skin cancer, prostate cancer is the most common cancer diagnosed among men in the United States, and about one in eight men will be diagnosed with the disease during their lifetime.
Columbia cancer researchers are testing a new chemotherapy regimen for patients with an invasive form of bladder cancer who have limited options beyond radical surgery if initial treatment fails.